Subjects With ApoA-I(Lys 107 →0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)
- 1 May 1997
- journal article
- case report
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (5) , 873-880
- https://doi.org/10.1161/01.atv.17.5.873
Abstract
Our purpose was to examine HDL metabolism in a Finnish kindred with a 3-bp deletion in the apolipoprotein (apo) A-I gene, resulting in a deletion of Lys 107 in the mature apoA-I. Patients with this mutation [apoA-I(Lys 107 →0)] have reduced plasma HDL cholesterol and lipoprotein (AI with AII) [Lp(AI w AII)] concentrations, but not Lp(AI) levels, compared with unaffected family members. Using primed constant infusions of [5,5,5- 2 H 3 ]leucine, we determined the residence time (RT) and absolute production rate (APR) of apoA-I and apoA-II entering plasma in two subpopulations of HDL particles: [Lp(AI) and Lp(AI w AII)] in three patients heterozygous for apoA-I(Lys 107 →0) and in seven healthy control subjects. In patients, the mean RT of apoA-I in Lp(AI) (3.75±1.68 days) was less than half that observed in control subjects (8.01±2.51 days, P <.05). The mean RT of apoA-I in Lp(AI w AII) was also lower in patients than in control subjects, but differences were not statistically significant (4.72±2.42 versus 6.50±2.19 days). The mean RT of apoA-II in Lp(AI w AII) was significantly lower in patients (5.24±1.65 days) than in control subjects (9.64±3.57 days, P <.05). The APR of apoA-I into Lp(AI) was twofold higher in patients (5.9±2.1 mg·kg −1 ·d −1 ) than in control subjects (2.5±0.9, P <.05). The APRs of apoA-I and apoA-II into Lp(AI w AII) were similar in patients and control subjects. Our results are consistent with the concept that patients heterozygous for the apoA-I(Lys 107 →0) mutation have enhanced fractional catabolism of apoA-I and apoA-II in both HDL subspecies, especially in Lp(AI), and an increase in apoA-I production only into Lp(AI), which may be compensatory. Therefore, only their Lp(AI w AII) levels are decreased.Keywords
This publication has 31 references indexed in Scilit:
- ApoA-IHelsinki(Lys107→0) Associated With Reduced HDL Cholesterol and LpA-I:A-II DeficiencyArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracellular cholesterol effluxBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Differential effect of subspecies of lipoprotein containing apolipoprotein A-I on cholesterol efflux from cholesterol-loaded macrophages: Functional correlation with lecithin : cholesterol acyltransferaseBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Investigation of lipoprotein kinetics using endogenous labeling with stable isotopesCurrent Opinion in Lipidology, 1992
- Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cellsAtherosclerosis, 1991
- Variant apolipoprotein AI as a major constituent of a human hereditary amyloidBiochemical and Biophysical Research Communications, 1988
- Early incorporation of cell-derived cholesterol into pre-.beta.-migrating high-density lipoproteinBiochemistry, 1988
- Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particlesBiochemical and Biophysical Research Communications, 1987
- Influence of weight reduction on plasma lipoproteins in obese patients.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1983
- Metabolism of High-Density Lipoprotein Apolipoproteins in Tangier DiseaseNew England Journal of Medicine, 1978